Secondary analysis of the EMPACT-MI trial reveals cardiovascular-kidney efficacy and safety of empagliflozin after acute myocardial infarction.

ABSTRACT: Data on the cardiovascular-kidney effects and safety of empagliflozin among patients with acute myocardial infarction are limited. EMPACT-MI (Study to Evaluate the Effect of Empagliflozin on Hospitalization for Heart Failure and Mortality in Patients with Acute Myocardial Infarction) was a double-blind, multicenter clinical trial that randomized 6,522 patients with acute myocardial infarction and risk for heart failure to empagliflozin or placebo. Here we show in this secondary analysis that the mean estimated glomerular filtration rate at baseline was 76.1 ml min^-1 1.73 m^-2 (s.d. = 19.9 ml min^-1 1.73 m^-2), with longitudinal kidney function data available for 1,152 (17.7%) treated patients from select countries. By 24 months

SUBMITTER: Aggarwal R 

PROVIDER: S-EPMC12170341 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature